Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston Veterans Affairs Healthcare System, Harvard Medical School, Boston, Massachusetts 02215, USA.
J Clin Endocrinol Metab. 2011 Oct;96(10):E1634-9. doi: 10.1210/jc.2011-0600. Epub 2011 Jul 27.
Preadipocyte factor 1 (pref-1) is increased in anorexia nervosa and is associated negatively with bone mineral density (BMD). No previous studies exist on pref-1 in women with exercise-induced hypothalamic amenorrhea (HA), which similar to anorexia nervosa, is an energy-deficiency state associated with hypoleptinemia.
Our objective was to evaluate whether pref-1 levels are also elevated and associated with low BMD and to assess whether leptin regulates pref-1 levels in women with HA.
Study 1 was a double-blinded, placebo-controlled randomized clinical trial of metreleptin administration in women with HA. Study 2 was an open-label study of metreleptin administration in low physiological, supraphysiological, and pharmacological doses in healthy women volunteers.
At Beth Israel Deaconess Medical Center, 20 women with HA and leptin levels higher than 5 ng/ml and nine healthy control women participated in study 1, and five healthy women participated in study 2.
For study 1, 20 HA subjects were randomized to receive either 0.08 mg/kg metreleptin (n = 11) or placebo (n = 9). For study 2, five healthy subjects received 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d, respectively.
Circulating pref-1 and leptin levels were measured.
Pref-1 was significantly higher in HA subjects vs. controls (P = 0.035) and negatively associated with BMD (ρ = -0.38; P < 0.01) and bone mineral content (ρ = -0.32; P < 0.05). Metreleptin administration did not alter pref-1 levels in any study reported herein.
Pref-1 is higher in HA subjects than controls. Metreleptin administration at low physiological, supraphysiological, and pharmacological doses does not affect pref-1 levels, suggesting that hypoleptinemia is not responsible for higher pref-1 levels and that leptin does not regulate pref-1.
在神经性厌食症患者中,前体脂肪因子 1(pref-1)的水平升高,并与骨密度(BMD)呈负相关。目前尚无关于运动诱导性下丘脑闭经(HA)患者中 pref-1 的研究,该病症与神经性厌食症相似,是一种与瘦素水平降低相关的能量缺乏状态。
我们的目的是评估 pref-1 水平是否也升高,并与低 BMD 相关,以及评估瘦素是否调节 HA 患者的 pref-1 水平。
研究 1 是一项在 HA 患者中进行的 metreleptin 给药的双盲、安慰剂对照随机临床试验。研究 2 是一项在健康女性志愿者中以低生理、超生理和药理剂量给予 metreleptin 的开放标签研究。
在贝斯以色列女执事医疗中心,20 名 HA 患者和瘦素水平高于 5ng/ml 的患者以及 9 名健康对照女性参加了研究 1,5 名健康女性参加了研究 2。
对于研究 1,20 名 HA 患者被随机分为接受 metreleptin(n=11)或安慰剂(n=9)治疗。对于研究 2,5 名健康受试者分别在进食和禁食条件下接受 0.01、0.1 和 0.3mg/kg 的 metreleptin,持续 1 天和 3 天。
循环 pref-1 和瘦素水平。
HA 患者的 pref-1 水平明显高于对照组(P=0.035),与 BMD(ρ=-0.38;P<0.01)和骨矿物质含量(ρ=-0.32;P<0.05)呈负相关。在本研究报告的任何研究中,metreleptin 给药均未改变 pref-1 水平。
HA 患者的 pref-1 水平高于对照组。在低生理、超生理和药理剂量下给予 metreleptin 不会影响 pref-1 水平,表明低瘦素血症不是导致 pref-1 水平升高的原因,并且瘦素不调节 pref-1。